314022-67-8

Basic information

• Product Name: N-(2,4-Difluorophenyl)-2-MethoxybenzaMide, 97%
• Synonyms: N-(2,4-Difluorophenyl)-2-MethoxybenzaMide, 97%
• CAS NO: 314022-67-8
• Molecular Formula: C₁₄H₁₁F₂NO₂
• Molecular Weight: 263.2394464
• Mol File: 314022-67-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(2,4-Difluorophenyl)-2-MethoxybenzaMide, 97%(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,4-Difluorophenyl)-2-MethoxybenzaMide, 97%(314022-67-8)
• EPA Substance Registry System: N-(2,4-Difluorophenyl)-2-MethoxybenzaMide, 97%(314022-67-8)

Safety Data

• Hazardous Substances Data: 314022-67-8(Hazardous Substances Data)

Upstream product

• 1441-87-8 salicyloyl chloride 
• 69-72-7 salicylic acid 
• 74-88-4 methyl iodide 

Relevant articles and documents

Modified salicylanilide and 3-phenyl-2 H -benzo[ e ][1,3]oxazine-2,4(3 H)-dione derivatives as novel inhibitors of osteoclast differentiation and bone resorption

Inhibition of osteoclast formation is a potential strategy to prevent inflammatory bone resorption and to treat bone diseases. In the present work, the purpose was to discover modified salicylanilides and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as potential antiosteoclastogenic agents. Their inhibitory effects on RANKL-induced osteoclastogenesis from RAW264.7 cells were evaluated by TRAP stain assay. The most potent compounds, 1d and 5d, suppressed RANKL-induced osteoclast formation and TRAP activity dose-dependently. The cytotoxicity assay on RAW264.7 cells suggested that the inhibition of osteoclastic bone resorption by these compounds did not result from their cytotoxicity. Moreover, both compounds downregulated RANKL-induced NF-κB and NFATc1 in the nucleus, suppressed the expression of osteoclastogenesis-related marker genes during osteoclastogenesis, and prevented osteoclastic bone resorption but did not impair osteoblast differentiation in MC3T3-E1. Therefore, these modified salicylanilides and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-diones could be potential lead compounds for the development of a new class of antiresorptive agents.

PHARMACEUTICAL COMPOSITION OF SALICYLANILIDE-DERIVED SMALL MOLECULES AND PREPARATION AND APPLICATION THEREOF

The present invention provides a pharmaceutical composition of salicylanilide-derived small molecules include: (a) a compound which structure is selected from formula I or formula II: (b) a pharmaceutically acceptable salt and excipient. The present invention also provides the synthesis method of the pharmaceutical composition and the application thereof.